You'll remember that
Astellas made a hostile offer for OSI Pharmaceuticals earlier in the month. Along with their offer, they
sued in Delaware to get the OSI board to consider the offer. Well, the
board has considered the offer ($52/sh cash, a 40% premium) and has rejected it .